Adaptive Biotechnologies (ADPT) Net Income towards Common Stockholders (2018 - 2026)

Adaptive Biotechnologies has disclosed Net Income towards Common Stockholders across 9 years of filings, most recently posting -$16.2 million for Q2 2026.

• In Q2 2026, Net Income towards Common Stockholders rose 36.67% year-over-year to -$16.2 million; the TTM figure through Jun 2026 stood at -$40.3 million (up 66.79% YoY), while the FY2025 annual figure was -$59.5 million, up 62.75% from the prior year.
• Net Income towards Common Stockholders came in at -$16.2 million for Q2 2026 at Adaptive Biotechnologies, up from -$20.0 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $9.5 million in Q3 2025 to a low of -$69.5 million in Q4 2023.
• Average Net Income towards Common Stockholders over 5 years is -$37.8 million, with a median of -$42.7 million recorded in 2022.
• Year-over-year, Net Income towards Common Stockholders tumbled 72.94% in 2023 and surged 129.74% in 2025.
• Over 5 years, Net Income towards Common Stockholders stood at -$40.2 million in 2022, then plunged by 72.94% to -$69.5 million in 2023, then soared by 51.46% to -$33.7 million in 2024, then surged by 59.73% to -$13.6 million in 2025, then declined by 19.36% to -$16.2 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$16.2 million in Q2 2026, -$20.0 million in Q1 2026, and -$13.6 million in Q4 2025.